Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative ColitisGlobeNewsWire · Oct 16, 2026
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 30, 2026
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Aug 25, 2026
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire · Aug 17, 2026Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$1.03 | -$11.25 | Miss |
| May 13, 2026 | -$2.73 | -$1.48 | Beat |
| Mar 10, 2026 | -$2.10 | -$1.81 | Beat |
| Nov 13, 2025 | -$2.25 | -$2.00 | Beat |
| Aug 13, 2025 | -$5.50 | -$4.50 | Beat |
| May 14, 2025 | -$12.50 | -$8.50 | Beat |